Oncogenic Aberrations of p16INK4/Cdkn2 and Cyclin D1 Cooperate to Deregulate G1 Control

Cancer Research

Volumn 55, Issue 21, 1995, Pages 4818-4823

  Lukas, Jiri ^a   Aagaard, Louise ^a   Strauss, Michael ^a,b   Bartek, Jiri ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b Max Planck Gesellschafi ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CYCLIN D1; CYCLINE; ONCOPROTEIN; PROTEIN P16; CYCLIN DEPENDENT KINASE; RETINOBLASTOMA PROTEIN;

ARTICLE; CELL CULTURE; CELL CYCLE G1 PHASE; CELL DIVISION; CHROMOSOME ABERRATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MOLECULAR GENETICS; NEOPLASM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; FIBROBLAST; GENE TRANSFER; HUMAN CELL; PRIORITY JOURNAL; RETINOBLASTOMA;

BASE SEQUENCE; CARRIER PROTEINS; CELL DIVISION; CHROMOSOME ABERRATIONS; CYCLIN D1; CYCLINS; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN; MOLECULAR SEQUENCE DATA; NEOPLASMS; ONCOGENE PROTEINS; PROTEIN P16; SUPPORT, NON-U.S. GOV'T; TUMOR CELLS, CULTURED;

EID: 0028970951     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stocken, E., Day, R. S., Johnson, B. E., and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Washington DC), 264: 436–440, 1994.
2. Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., and Carson, D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond.), 368: 753–756, 1994.
3. Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., and Sidransky, D. 5’ CpG island methylation is associated with transcriptional silencing of the tumor suppressor pl6/CDKN2/MTSl in human cancers. Nat. Med., 1: 686–692, 1995.
4. Okamoto, A., Demetrick, D. J., Spillare, E. A., Hagiwara, K., Hussain, S. P., Bennett, W. P., Forrester, K., Gerwin, B., Serrano, M., Beach, D. H., and Harris, C. C. Mutations and altered expression of pl6,nk4 in human cancer. Proc. Natl. Acad. Sci. USA, 91: 11045–11049, 1994.
5. Hunter, T., and Pines, J. Cyclins and cancer II: cyclin D and cdk inhibitors come of age. Cell, 79: 573–582, 1994.
6. Sherr, C. J., and Roberts, J. M. Inhibitors of mammalian G, cyclin-dependent kinases. Genes & Dev., 9: 1149–1163, 1995.
7. Lammie, G. A., Fantl, V., Smith, R., Schuuring, E., Brookes, S., Michalides, R., Dickson, C., Arnold, A., and Peters, G. D11S287, a putative oncogene on chromosome llql3, is amplified and expressed in squamous cell and mammary carcinomas and linked to bcl-1. Oncogene, 6: 439–444, 1991.
8. Jiang, W., Zhang, Y.-J., Kahn, S. M., Hollstein, M. C., Santella, R. M., Lu, S.-H., Harris, C. C., Montesano, R., and Weinstein, I. B. Altered expression of the cyclin Dl and retinoblastoma genes in human esophageal cancer. Proc. Natl. Acad. Sci. USA, 90: 9026–9030, 1993.
9. Motokura, T., and Arnold, A. Cyclins and oncogenesis. Biochim. Biophys. Acta, 1155: 63–78, 1993.
10. Schmidt, E. E., Ichimura, K., Reifenberger, G., and Collins, V. P. CDKN2 (pl6/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res., 54: 6321–6324, 1994.
11. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell, 81:323–330, 1995.
12. Serrano, M., Hannon, G. J., and Beach, D. A regulatory motif in cell-cycle control causing specific inhibition of cyclin D/cdk4. Nature (Lond.), 366: 704–707, 1993.
13. Sherr, C. J. G1 phase progression: cycling on cue. Cell, 79: 551–555, 1994.
14. Lukas, J., Müller, H., Bartkova, J., Spitkovsky, D., Kjerulff, A. A., Jansen-Dürr, P., Strauss, M., and Bartek, J. DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin Dl function in Gl. J. Cell Biol., 125: 625–638, 1994.
15. Lukas, J., Bartkova, J., Rohde, M., Strauss, M., and Bartek, J. Cyclin Dl is dispensable for Gl control in retinoblastoma gene-deficient cells independently of cdk4 activity. Mol. Cell. Biol., 15: 2600–2611, 1995.
16. Tarn, S. W., Theodoras, A. M., Shay, J. W., Draetta, G. F., and Pagano, M. Differential expression and regulation of cyclin Dl protein in normal and tumor human cells: association with cdk4 is required for cyclin Dl function in G1 progression. Oncogene, 9: 2663–2674, 1994.
17. Koh, J., Enders, G. H., Dynlacht, B. D., and Harlow, E. Tumour-derived pl6 alleles encoding proteins defective in cell-cycle inhibition. Nature (Lond.), 375: 506–510, 1995.
18. Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G., and Bartek, J. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature (Lond.), 375: 503–506, 1995.
19. Guan, K., Jenkins, C. W., Li, Y., Nichols, M. A., Wu, X., O'Keefe, C. L., Matera A. O., and Xiong, Y. Growth suppression by pl8, a pl6 and pl4-related CDK6 inhibitor, correlates with wild-type pRB function. Genes & Dev., 8: 2939–2952, 1994.
20. Medema, R. H., Herrera, R. E., Lam, F., and Weinberg, R. A. Growth suppression by pl6mk4 requires functional retinoblastoma protein. Proc. Natl. Acad. Sci. USA, 92: 6289–6293, 1995.
21. Bartkova, J., Lukas, J., Müller, H., Lutzhøft, D., Strauss, M., and Bartek, J. Cyclin Dl protein expression and function in human breast cancer. Int. J. Cancer, 57: 353–361, 1994.
22. Otterson, G. A., Kratzke, R. A., Coxon, A., Kim, Y. W., and Kaye, F. J. Absence of pl6lnk4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene, 9: 3375–3378, 1994.
23. Parry, D., Bates, S., Mann, D. J., and Peters, G. Lack of cyclin D-cdk complexes in RB-negative cells correlates with high levels of p16,nk4/MTS1 tumour suppressor gene product. EMBO J., 14: 503–511, 1995.
24. Aagaard, L., Lukas, J., Bartkova, J., Kjerulff, A. A., Strauss, M., and Bartek, J. Aberrations of pl61nk4 and retinoblastoma tumor-suppressor genes occur in distinct sub-sets of human cancer cell lines. Int. J. Cancer, 61: 115–120, 1995.
25. Lukas, J., Pagano, M., Staskova, Z., Draetta, G., and Bartek, J. Cyclin Dl protein oscillates and is essential for cell cycle progression in human tumour cell lines. Oncogene, 9: 707–718, 1994.
26. Lukas, J., Jadayel, D., Bartkova, J., Nacheva, E., Dyer, M. J. S., Strauss, M., and Bartek, J. BCL-1/cyclin Dl oncoprotein oscillates and subverts the G1 phase control in B-cell neoplasms carrying the t(11;14) translocation. Oncogene, 9: 2159–2167, 1994.
27. Seto, M., Yamamoto, K., Iida, S., Akao, Y., Utsumi, K. R., Kubonishi, I., Miyoshi, I., Ohtsuki, I., Yawata, Y., Namba, M., Motokura, I., Arnold, A., Takahasi, T., and Ueda, R. Gene rearrangement and overexpression of PRAD1 in lymphoid malignancy with t(11;14Xql3;q32) translocation. Oncogene, 7: 1401–1406, 1992.
28. Bodrug, S. E., Warner, B. J., Bath, M. L., Lindeman, G. J., Harris, A. W., and Adams, J. M. Cyclin Dl transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J., 13: 2124–2130, 1994.
29. Lovec, H., Grzeschiczek, A., Kowalski, M.-B., and Möröy, T. Cyclin Dl/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J., 75: 3487–3495, 1994.
30. Wang, T. C., Cardiff, R. D., Zukerberg, L., Lees, E., Arnold, A., and Schmidt, E. V. Mammary hyperplasia and carcinoma in MMTV-cyclin Dl transgenic mice. Nature (Lond.), 369: 669–671, 1994.